HCA shares slide after Q1 results as investors focus on soft volumes and unchanged full-year outlook

HCA Healthcare, Inc. (HCA) is down 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to an earnings-day reset in expectations: HCA posted solid first-quarter results but kept its full-year 2026 guidance unchanged, which can read as cautious when the market was positioned for a raise. Investors also seemed to focus on weaker-than-usual seasonal utilization trends, which may pressure growth assumptions for the rest of the year.

Details:

HCA reported first-quarter 2026 revenue growth and higher earnings versus the prior year, alongside higher Adjusted EBITDA.

The company said it did not see a typical seasonal lift in volumes, with respiratory-related admissions and respiratory-related ER visits materially lower year over year, and noted a January winter storm that hurt volumes in certain markets.

HCA reaffirmed (rather than increased) its previously issued full-year 2026 guidance ranges, including commentary that guidance assumptions include public policy developments and potential impacts tied to health insurance exchange reforms and the expiration of enhanced premium tax credits.

Management highlighted ongoing capital returns (share repurchases during the quarter and a declared quarterly dividend), but those actions did not offset near-term concerns around utilization and the outlook.

Sources:

HCA Healthcare Investor Relations, Bloomberg Law, RTTNews

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HCA Insider Trading Activity

$HCA insiders have traded $HCA stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:

SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) has made 0 purchases and 2 sales selling 5,586 shares for an estimated $2,747,527.
CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 1,500 shares for an estimated $747,135

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive HCA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HCA Hedge Fund Activity

We have seen 607 institutional investors add shares of $HCA stock to their portfolio, and 619 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,306,304 shares (-77.3%) from their portfolio in Q4 2025, for an estimated $2,477,301,085
FMR LLC added 1,928,240 shares (+101.2%) to their portfolio in Q4 2025, for an estimated $900,218,126
BANK OF AMERICA CORP /DE/ removed 1,319,037 shares (-63.6%) from their portfolio in Q4 2025, for an estimated $615,805,613
PACER ADVISORS, INC. removed 911,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $425,354,278
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 649,058 shares (+4545.5%) to their portfolio in Q4 2025, for an estimated $303,019,217
JPMORGAN CHASE & CO removed 627,849 shares (-21.0%) from their portfolio in Q4 2025, for an estimated $293,117,584
DIAMOND HILL CAPITAL MANAGEMENT INC removed 618,170 shares (-92.9%) from their portfolio in Q4 2025, for an estimated $288,598,846

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$HCA Analyst Ratings

Wall Street analysts have issued reports on $HCA in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 01/28/2026
Barclays issued a "Overweight" rating on 01/28/2026
Deutsche Bank issued a "Buy" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/28/2026
Oppenheimer issued a "Outperform" rating on 01/28/2026
Morgan Stanley issued a "Underweight" rating on 12/15/2025
UBS issued a "Buy" rating on 10/27/2025

To track analyst ratings and price targets for $HCA, check out Quiver Quantitative's $HCA forecast page.

$HCA Price Targets

Multiple analysts have issued price targets for $HCA recently. We have seen 18 analysts offer price targets for $HCA in the last 6 months, with a median target of $550.5.

Here are some recent targets:

Ryan Langston from TD Cowen set a target price of $561.0 on 03/10/2026
Ann Hynes from Mizuho set a target price of $585.0 on 02/25/2026
Andrew Mok from UBS set a target price of $635.0 on 02/23/2026
Benjamin Rossi from JP Morgan set a target price of $535.0 on 02/20/2026
David Toung from Argus Research set a target price of $560.0 on 02/06/2026
Stephen Baxter from Wells Fargo set a target price of $481.0 on 01/30/2026
Michael Wiederhorn from Oppenheimer set a target price of $540.0 on 01/28/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.